GSK3B and breast cancer: Wang et al. [43] conducted an association study to determine whether common genetic variations in six genes (APC, AXIN1, AXIN2, CSNK1D, CSNK1E, and GSK3B) that encode the destruction complex of the Wnt/β-catenin signaling pathway account in part for the contribution of the pathway to BC risk.